Zhongguo aizheng zazhi (Jun 2022)

Detection of CD30 expression in lymphomas: status and challenges

  • LI Xiaoqiu, CD30 Positive Lymphoma Pathology Expert Group

DOI
https://doi.org/10.19401/j.cnki.1007-3639.2022.06.005
Journal volume & issue
Vol. 32, no. 6
pp. 512 – 518

Abstract

Read online

CD30, a member of tumor necrosis factor receptor family, is expressed in a variety of lymphoma subtypes, such as classic Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL). In addition to its diagnostic and prognostic values, CD30 has now been recognized as an effective target for antibody drug conjugate (ADC). With the progress of multiple clinical trials involving the anti-CD30-targeted therapy, a standardized detection and assessment of CD30 expression in lymphoma cases appear necessary. We thus reviewed in this article the CD30 expression patterns and the challenges on the CD30 detection and assessment in different lymphomas.

Keywords